secwatch.observer — SEC 8-K summary
======================================

Issuer:     Panbela Therapeutics, Inc. (—)
CIK:        0001029125
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001437749-24-017059
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Panbela Q1 net loss $7.1M; ASPIRE trial interim analysis delayed to Q1 2025 due to lower event rate
--------------------------------------------------------------------------------

- ASPIRE trial interim OS analysis delayed to Q1 2025; lower-than-expected event rate may signal improved survival.
- ASPIRE enrollment >50%; complete enrollment of ~600 patients expected by Q1 2025.
- Q1 2024 R&D expenses $5.5M (up from $3.5M YoY) driven by ASPIRE expansion; net loss per share $2.28.
- Cash $262k as of March 31; closed $9.0M public offering in January; $0.8M nondilutive payment from US WorldMeds in April.
- Stock moved to OTCQB; new US and Canada patent for eflornithine/sulindac fixed dose combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029125/000143774924017059/0001437749-24-017059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029125/000143774924017059/pbla20240514_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-017059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer